Fig. 8: m6A modification is involved in the upregulation of circSLC38A1 in BC cells.

A 4 BC cells were treated with or without 5 µM 5-aza-dC for 7 days, and circSLC38A1 expression was measured by qRT-PCR. B 4 BC cells were treated with or without 2 µM SAHA for 24 h, and circSLC38A1 expression was measured by qRT-PCR. C 4 BC cells were treated with or without 2 µM NAB for 24 h, and circSLC38A1 expression was measured. D RIP assays shows the association between IGF2BP2 or IGF2BP3 with circSLC38A1 in T24 cells. Top, fold enrichment representing RNA levels associated with IGF2BP2 or IGF2BP3 relative to IgG, IgG antibody served as a control. Bottom, agarose gel electrophoresis for products of RIP assay. E Three m6A modification sites on circSLC38A1 with high or very high confidence were identified by using online software tool SRAMP. F m6A RIP qRT-PCR analysis of circSLC38A1 in T24 and SV-HUC-1 cells. G The expression levels of circSLC38A1 in T24 cells transfected with vector control or METTL3 overexpression plasmid were measured by qRT-PCR. H The expression levels of circSLC38A1 in T24 cells transfected with si-NC or METTL3 siRNAs were measured by qRT-PCR. I The expression levels of circSLC38A1 in T24 cells transfected with vector control or FTO overexpression plasmid were measured by qRT-PCR. J The expression levels of circSLC38A1 in T24 cells transfected with si-NC or FTO siRNAs were measured by qRT-PCR. Data represent mean ± SD from three independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001.